Advertisement
Singapore markets closed
  • Straits Times Index

    3,300.00
    -4.00 (-0.12%)
     
  • S&P 500

    5,497.66
    +10.63 (+0.19%)
     
  • Dow

    38,908.71
    +73.85 (+0.19%)
     
  • Nasdaq

    17,897.56
    +35.32 (+0.20%)
     
  • Bitcoin USD

    64,927.89
    +41.02 (+0.06%)
     
  • CMC Crypto 200

    1,347.65
    -35.02 (-2.53%)
     
  • FTSE 100

    8,259.26
    +54.15 (+0.66%)
     
  • Gold

    2,376.30
    +29.40 (+1.25%)
     
  • Crude Oil

    82.24
    +0.67 (+0.82%)
     
  • 10-Yr Bond

    4.2830
    +0.0660 (+1.57%)
     
  • Nikkei

    38,633.02
    +62.26 (+0.16%)
     
  • Hang Seng

    18,335.32
    -95.07 (-0.52%)
     
  • FTSE Bursa Malaysia

    1,592.69
    -7.10 (-0.44%)
     
  • Jakarta Composite Index

    6,819.32
    +92.40 (+1.37%)
     
  • PSE Index

    6,344.56
    -21.47 (-0.34%)
     

Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.

PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

ADVERTISEMENT

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G